Segment Disclosure

12 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Segment Disclosure

Note 17. Segment Disclosure

The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset based metrics. Therefore, the information below is presented only for revenues and long‑lived tangible assets by geographic areas.

Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands):

	Years ended June 30,
	2021		2020		2019
Americas	$	105,878	$	128,562	$	135,683
Europe, Middle East, India and Africa		121,568		119,989		149,095
Asia Pacific, excluding Japan and China		26,425		31,297		44,136
Japan		62,636		72,688		70,214
China		79,782		30,392		19,657
Total	$	396,289	$	382,928	$	418,785

Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands):

Information regarding geographic areas in which the Company has long‑lived tangible assets is as follows (in thousands):

	June 30, 2021		June 30, 2020
Americas	$	10,588	$	12,807
Europe, Middle East, India and Africa		265		373
Asia Pacific, excluding Japan and China		170		126
Japan		701		1,183
China		608		860
Total	$	12,332	$	15,349